JP2000503534A5 - - Google Patents

Download PDF

Info

Publication number
JP2000503534A5
JP2000503534A5 JP1997525405A JP52540597A JP2000503534A5 JP 2000503534 A5 JP2000503534 A5 JP 2000503534A5 JP 1997525405 A JP1997525405 A JP 1997525405A JP 52540597 A JP52540597 A JP 52540597A JP 2000503534 A5 JP2000503534 A5 JP 2000503534A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1997525405A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000503534A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1997/000370 external-priority patent/WO1997025446A1/en
Publication of JP2000503534A publication Critical patent/JP2000503534A/ja
Publication of JP2000503534A5 publication Critical patent/JP2000503534A5/ja
Ceased legal-status Critical Current

Links

JP9525405A 1996-01-05 1997-01-03 アデノウイルスベクターのリコンビナーゼ媒介生成 Ceased JP2000503534A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58370396A 1996-01-05 1996-01-05
US08/583,703 1996-01-05
PCT/US1997/000370 WO1997025446A1 (en) 1996-01-05 1997-01-03 Recombinase-mediated generation of adenoviral vectors

Publications (2)

Publication Number Publication Date
JP2000503534A JP2000503534A (ja) 2000-03-28
JP2000503534A5 true JP2000503534A5 (enExample) 2004-11-11

Family

ID=24334219

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9525405A Ceased JP2000503534A (ja) 1996-01-05 1997-01-03 アデノウイルスベクターのリコンビナーゼ媒介生成

Country Status (7)

Country Link
US (1) US6156497A (enExample)
EP (1) EP0927263A1 (enExample)
JP (1) JP2000503534A (enExample)
AU (1) AU1695197A (enExample)
CA (1) CA2239366A1 (enExample)
NZ (1) NZ330553A (enExample)
WO (1) WO1997025446A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6730507B1 (en) 1993-06-24 2004-05-04 Merck & Co., Inc. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration
US6756226B2 (en) * 1994-05-31 2004-06-29 Frank L. Graham Enhanced system for construction of adenovirus vectors
US6379943B1 (en) * 1999-03-05 2002-04-30 Merck & Co., Inc. High-efficiency Cre/loxp based system for construction of adenovirus vectors
US6974694B2 (en) 1995-06-07 2005-12-13 Advec, Inc. Adenoviruses for control of gene expression
US5888732A (en) 1995-06-07 1999-03-30 Life Technologies, Inc. Recombinational cloning using engineered recombination sites
US6720140B1 (en) 1995-06-07 2004-04-13 Invitrogen Corporation Recombinational cloning using engineered recombination sites
US6964861B1 (en) 1998-11-13 2005-11-15 Invitrogen Corporation Enhanced in vitro recombinational cloning of using ribosomal proteins
US6143557A (en) 1995-06-07 2000-11-07 Life Technologies, Inc. Recombination cloning using engineered recombination sites
FR2749857B1 (fr) * 1996-06-12 1998-08-14 Centre Nat Rech Scient Generation de molecules replicatives in vivo
CA2272121A1 (en) * 1996-11-19 1998-05-28 Uab Research Foundation Chimeric retrovirus/adenovirus system
US6403370B1 (en) * 1997-02-10 2002-06-11 Genstar Therapeutics Corporation Oncolytic/immunogenic complementary-adenoviral vector system
US7030096B1 (en) * 1997-02-13 2006-04-18 Albert Einstein College Of Medicine Of Yeshiva University Method of enhancing relaxation of penile smooth muscle by introduction of DNA encoding maxi-K potassium channel protein
US5851808A (en) 1997-02-28 1998-12-22 Baylor College Of Medicine Rapid subcloning using site-specific recombination
CA2285666C (en) 1997-03-21 2010-12-14 Enzo Therapeutics, Inc. Vectors and viral vectors, and packaging cell lines for propagating same
WO1998046778A1 (en) * 1997-04-11 1998-10-22 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Transgenomic viruses and the use thereof
DE69831417T2 (de) 1997-09-23 2006-06-22 Genvec, Inc. Duale selektionkassette und sie enthaltende plasmide
IL135776A0 (en) * 1997-10-24 2001-05-20 Life Technologies Inc Recombinational cloning using nucleic acids having recombination sites
US7351578B2 (en) 1999-12-10 2008-04-01 Invitrogen Corp. Use of multiple recombination sites with unique specificity in recombinational cloning
DE19807265C2 (de) * 1998-02-20 2000-01-05 Centeon Pharma Gmbh Adenoviraler Transfervektor für den Gentransport einer DNA-Sequenz
US6413776B1 (en) * 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
US6576463B1 (en) 1999-01-15 2003-06-10 The Regents Of The University Of California Hybrid vectors for gene therapy
WO2000052027A1 (en) 1999-03-02 2000-09-08 Invitrogen Corporation Compositions and methods for use in recombinational cloning of nucleic acids
JP2003518915A (ja) * 1999-03-05 2003-06-17 メルク アンド カンパニー インコーポレイテッド アデノウイルスベクターを構築する増強された系
EP2210948A3 (en) * 1999-12-10 2010-10-06 Life Technologies Corporation Use of multiple recombination sites with unique specificity in recombinational cloning
US7052904B2 (en) 2000-01-31 2006-05-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Hybrid adeno-retroviral vector for the transfection of cells
US7244560B2 (en) 2000-05-21 2007-07-17 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
EP1320620B1 (en) 2000-09-25 2015-01-21 The Regents Of The University Of Michigan Production of viral vectors
US7723102B2 (en) * 2000-09-28 2010-05-25 Bayer Corporation Enhanced transfection system
US7226779B2 (en) 2001-01-30 2007-06-05 The United States Of America As Represented By The Department Of Health And Human Services Hybrid adenoviral vector
US6943012B2 (en) * 2001-03-26 2005-09-13 The Board Of Trustees Of The Leland Stanford Junor University Helper dependent adenoviral vector system and methods for using the same
WO2002085287A2 (en) * 2001-04-18 2002-10-31 Genstar Therapeutics Corp. Minimal adenoviral vectors for immunization
WO2003062400A2 (en) * 2002-01-24 2003-07-31 The Scripps Research Institute Fiber shaft modifications for efficient targeting
US8304233B2 (en) 2002-06-04 2012-11-06 Poetic Genetics, Llc Methods of unidirectional, site-specific integration into a genome, compositions and kits for practicing the same
US20040203133A1 (en) * 2003-01-07 2004-10-14 Anja Ehrhardt Helper dependent adenoviral vector system and methods for using the same
WO2004083404A2 (en) * 2003-03-19 2004-09-30 Isogenis, Inc. Gene therapy vectors having reduced immunogenicity based on cd8 alpha-chain
EP1613757A2 (en) 2003-03-28 2006-01-11 The Scripps Research Institute Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes
ATE469984T1 (de) 2003-12-01 2010-06-15 Life Technologies Corp Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon
US20090053249A1 (en) * 2004-07-20 2009-02-26 Yan Qi Specific Inhibition of Autoimmunity and Diseases Associated With Autoantigens
PL1804835T3 (pl) 2004-09-13 2010-11-30 Genzyme Corp Konstrukty multimeryczne
AR059089A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
CA2641359C (en) 2006-02-09 2022-10-04 Genzyme Corporation Slow intraventricular delivery
US8871515B2 (en) 2008-09-17 2014-10-28 Isogenis, Inc. Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof
JP2023517779A (ja) 2020-03-15 2023-04-26 プロテイネア,インコーポレーテッド 昆虫における組換えタンパク質の産生

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1293460C (en) * 1985-10-07 1991-12-24 Brian Lee Sauer Site-specific recombination of dna in yeast
EP0701401A4 (en) * 1993-04-08 1997-07-16 Genetic Therapy Inc ADENOVIRAL VECTORS INCLUDING LUNG SURFACE PROTEIN-ENCODING DNA
US5919676A (en) * 1993-06-24 1999-07-06 Advec, Inc. Adenoviral vector system comprising Cre-loxP recombination
US6686200B1 (en) * 1993-08-31 2004-02-03 Uab Research Foundation Methods and compositions for the large scale production of recombinant adeno-associated virus
CA2192442C (en) * 1994-06-10 2007-09-25 Imre Kovesdi Complementary adenoviral vector systems and cell lines
US5650309A (en) * 1995-05-16 1997-07-22 The Regents Of The University Of California Viral vectors

Similar Documents

Publication Publication Date Title
JP2000514445A5 (enExample)
JP2000505328A5 (enExample)
JP2002506542A5 (enExample)
JP2000516112A5 (enExample)
JP2000509608A5 (enExample)
JP2000505564A5 (enExample)
JP2001500665A5 (enExample)
JP2000500076A5 (enExample)
JP2001506453A5 (enExample)
JP2000506880A5 (enExample)
JP2000515856A5 (enExample)
JP2001505165A5 (enExample)
JP2000507909A5 (enExample)
JP2000517347A5 (enExample)
JP2000507420A5 (enExample)
JP2001506743A5 (enExample)
JP2001502299A5 (enExample)
JP2000503249A5 (enExample)
JP2000508592A5 (enExample)
JP2000503534A5 (enExample)
JP2001501612A5 (enExample)
JP2000507547A5 (enExample)
JP2001501065A5 (enExample)
JP2000517082A5 (enExample)
JP2000505355A5 (enExample)